Clovis Oncology (CLVS) soars on upgrade

Clovis Oncology, Inc. CLVS shares climbed 11.1% to $86.00. Analysts at Goldman Sachs upgraded Clovis Oncology from neutral to buy and raised the price target from $60 to $66. Share volume was 988,000, compared to an all-day average of 550,000
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!